Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
QIFENG
873169
5
LAISAI LASER
871263
CN Stock MarketDetailed Quotes
300683 Wuhan Hiteck Biological Pharma
- 22.86
- -0.21-0.91%
Market Closed May 9 15:00 CST
2.99BMarket Cap-44.82P/E (TTM)
23.15High22.75Low9.93KlotVolume23.00Open23.07Pre Close22.76MTurnover0.81%Turnover RatioLossP/E (Static)130.89MShares32.6552wk High1.26P/B2.79BFloat Cap19.0052wk Low27.68Limit Up122.06MShs Float84.71Historical High18.46Limit Down1.73%Amplitude18.67Historical Low0.13Dividend TTM22.91Avg Price5.56KlotAsk0.57%Div YieldTTM100Lot Size4.08KlotBid
Wuhan Hiteck Biological Pharma Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 18.79%156.67M | 7.75%648.97M | 2.87%450.99M | -0.64%284.62M | -4.87%131.89M | -12.54%602.28M | -19.80%438.43M | -26.03%286.45M | -16.59%138.64M | 12.03%688.63M |
| Operating revenue | 18.79%156.67M | 7.75%648.97M | 2.87%450.99M | -0.64%284.62M | -4.87%131.89M | -12.54%602.28M | -19.80%438.43M | -26.03%286.45M | -16.59%138.64M | 12.03%688.63M |
| Other operating revenue | ---- | -58.06%3.27M | ---- | -46.91%4.78M | ---- | -1.04%7.8M | ---- | 197.16%9M | ---- | 21.59%7.89M |
| Total operating cost | -6.86%172.86M | 3.67%740.49M | 5.37%533.19M | 3.46%341.12M | 20.19%185.59M | 3.34%714.28M | -4.78%506.04M | -8.91%329.72M | -4.45%154.42M | 14.83%691.22M |
| Operating cost | 9.95%87.13M | 7.49%370.92M | 0.92%246.97M | -6.28%154.34M | 1.67%79.25M | -2.77%345.06M | -14.42%244.73M | -19.26%164.68M | -6.43%77.95M | 34.02%354.88M |
| Operating tax surcharges | 14.11%1.62M | 29.93%7.11M | 28.80%5.04M | 23.65%3.38M | 23.93%1.42M | -2.96%5.47M | -3.49%3.91M | -0.65%2.73M | -4.12%1.15M | 58.69%5.64M |
| Operating expense | 23.79%34.4M | -1.60%126.61M | 0.84%100.16M | -5.13%64.06M | -11.48%27.79M | 1.55%128.66M | 2.63%99.32M | 14.04%67.53M | 1.64%31.4M | -13.02%126.71M |
| Administration expense | -51.71%23.87M | 5.23%119.26M | 30.18%95.13M | 28.27%62.11M | 114.77%49.44M | 20.80%113.33M | 7.49%73.08M | 8.18%48.42M | 15.88%23.02M | -3.58%93.81M |
| Financial expense | -386.69%-1.18M | 28.11%-5.13M | 45.43%-3.14M | 63.66%-1.73M | 92.64%-241.53K | 36.51%-7.14M | 34.95%-5.75M | 25.64%-4.77M | 3.32%-3.28M | 10.32%-11.25M |
| -Interest expense (Financial expense) | -64.48%422.27K | -4.11%2.3M | 19.42%2.05M | 29.68%1.41M | 222.14%1.19M | 114.35%2.39M | 47.68%1.72M | 11.54%1.09M | -28.95%369.05K | 124.92%1.12M |
| -Interest Income (Financial expense) | -5.69%-1.71M | 18.54%-8.14M | 27.97%-5.61M | 42.13%-3.53M | 57.45%-1.62M | 22.29%-9.99M | 24.79%-7.79M | 18.35%-6.11M | 5.69%-3.8M | 5.45%-12.86M |
| Research and development | -3.31%27.01M | -5.55%121.75M | -1.88%89.03M | 15.33%58.97M | 15.47%27.94M | 6.15%128.9M | 6.16%90.74M | -11.37%51.13M | -18.70%24.2M | 17.71%121.43M |
| Credit Impairment Loss | -95.31%26.48K | -667.79%-7.49M | -84.99%324.45K | -65.49%722.16K | -40.39%564.6K | 74.31%-974.97K | 9,122.68%2.16M | 253.44%2.09M | 122.90%947.22K | -115.97%-3.79M |
| Asset Impairment Loss | -117.66%-3.13M | 64.83%-21.15M | -198.90%-1.67M | -145.44%-1.41M | 370.69%17.7M | -81.03%-60.12M | 118.76%1.69M | 148.90%3.11M | --3.76M | -183.99%-33.21M |
| Other net revenue | -94.72%1.36M | 150.87%15.81M | 34.08%32.9M | 35.29%27.71M | 179.60%25.81M | -635.32%-31.08M | 276.72%24.53M | 1,327.85%20.48M | 651.66%9.23M | -149.24%-4.23M |
| Fair value change income | -68.33%1.84M | -147.88%-908.85K | -60.34%4.62M | -10.43%6.1M | 149.25%5.81M | -85.02%1.9M | 241.85%11.65M | 1,143.19%6.81M | -10.20%2.33M | 3,903.39%12.67M |
| Invest income | 68.44%402.76K | 6.46%16.7M | 152.12%7.53M | 90.13%4.08M | 10,050.76%239.11K | 42.06%15.69M | -44.36%2.99M | -63.66%2.15M | -98.48%2.36K | -23.00%11.04M |
| -Including: Investment income associates | ---- | 57.16%-1.19M | ---- | ---- | ---- | -15.16%-2.77M | ---- | ---- | ---- | -9,453.53%-2.4M |
| Asset deal income | ---- | 81.82%-65.22K | 97.93%-45.09K | -210.95%-43.5K | -210.95%-43.5K | -282.04%-358.67K | -828.31%-2.18M | 143.06%39.21K | --39.21K | 48.12%-93.88K |
| Other revenue | 43.74%2.22M | 124.49%28.72M | 168.98%22.13M | 190.92%18.26M | -28.26%1.54M | 39.69%12.79M | 28.58%8.23M | 57.06%6.28M | -17.65%2.15M | 11.53%9.16M |
| Operating profit | 46.82%-14.83M | 47.08%-75.71M | -14.47%-49.31M | -26.34%-28.79M | -325.78%-27.89M | -1,997.07%-143.07M | -298.19%-43.07M | -185.32%-22.78M | -212.60%-6.55M | -131.97%-6.82M |
| Add:Non operating Income | 1,063.38%43.58K | -32.67%115.85K | 82.57%222.45K | -70.62%32.95K | -96.16%3.75K | -59.40%172.06K | -43.20%121.85K | -32.71%112.15K | -96.69%97.53K | -28.81%423.83K |
| Less:Non operating expense | 85.40%1.04M | -49.96%4.55M | -60.54%2.45M | -64.98%716.34K | 54.39%559.25K | 537.43%9.09M | 697.99%6.22M | 265.72%2.05M | 59.65%362.23K | -3.65%1.43M |
| Total profit | 44.37%-15.82M | 47.27%-80.14M | -4.81%-51.54M | -19.22%-29.47M | -317.39%-28.45M | -1,842.57%-151.99M | -332.29%-49.17M | -193.94%-24.72M | -179.82%-6.82M | -138.25%-7.82M |
| Less:Income tax cost | 87.16%-1.41M | 73.17%-6.37M | 52.24%-9.34M | 57.73%-5.03M | -114.80%-10.95M | -32,106.33%-23.74M | -453.74%-19.56M | -1,228.50%-11.9M | -228.44%-5.1M | 100.78%74.18K |
| Net profit | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M | -219.90%-29.62M | -150.74%-12.82M | -117.00%-1.72M | -126.31%-7.9M |
| Net profit from continuing operation | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M | -219.90%-29.62M | -150.74%-12.82M | -117.00%-1.72M | -126.31%-7.9M |
| Less:Minority Profit | 48.48%-487.48K | 40.42%-4.42M | 22.73%-2.45M | 0.90%-1.67M | -288.92%-946.15K | -221.02%-7.42M | -154.04%-3.18M | -126.45%-1.69M | -110.14%-243.28K | 159.73%6.13M |
| Net profit of parent company owners | 15.81%-13.93M | 42.60%-69.35M | -50.32%-39.74M | -104.58%-22.77M | -1,024.00%-16.55M | -761.20%-120.82M | -240.47%-26.44M | -158.96%-11.13M | -119.14%-1.47M | -150.73%-14.03M |
| Earning per share | ||||||||||
| Basic earning per share | 15.38%-0.11 | 43.01%-0.53 | -42.86%-0.3 | -88.89%-0.17 | -550.00%-0.13 | -745.45%-0.93 | -240.00%-0.21 | -160.00%-0.09 | -133.33%-0.02 | -142.31%-0.11 |
| Diluted earning per share | 15.38%-0.11 | 43.01%-0.53 | -42.86%-0.3 | -88.89%-0.17 | -550.00%-0.13 | -745.45%-0.93 | -240.00%-0.21 | -160.00%-0.09 | -133.33%-0.02 | -142.31%-0.11 |
| Other composite income | ||||||||||
| Total composite income | 17.57%-14.42M | 42.48%-73.77M | -42.48%-42.2M | -90.68%-24.44M | -919.75%-17.49M | -1,523.72%-128.24M | -219.90%-29.62M | -150.74%-12.82M | -117.00%-1.72M | -126.31%-7.9M |
| Total composite income of parent company owners | 15.81%-13.93M | 42.60%-69.35M | -50.32%-39.74M | -104.58%-22.77M | -1,024.00%-16.55M | -761.20%-120.82M | -240.47%-26.44M | -158.96%-11.13M | -119.14%-1.47M | -150.73%-14.03M |
| Total composite income of minority owners | 48.48%-487.48K | 40.42%-4.42M | 22.73%-2.45M | 0.90%-1.67M | -288.92%-946.15K | -221.02%-7.42M | -154.04%-3.18M | -126.45%-1.69M | -110.14%-243.28K | 159.73%6.13M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting